Sort
30,917 grants matching “tumor microenvironment”
Molecular Mechanisms Regulating TLR Signaling and Macrophage Activation.
$400,000Shao-Cong Sun · University Of Tx Md Anderson Can Ctr · R01 · FY2019 · AI
Phase I/II Randomized Tiral of Adoptive Lymphocyte Transfer in Ovarian Cancer
$400,000George Coukos · University Of Pennsylvania · R01 · FY2013 · FD
A novel MICA/B based tumor-centric bispecific antibody that enhances NK cell activity in a hostile tumor microenvironment
$400,000Hemanta Baruah · Aakha Biologics Inc. · R43 · FY2024 · CA
Image-Based Phenotyping of Hepatocellular Carcinoma Cell Survival Under Ischemic Stress: Toward Metabolic Imaging of Cancer Dormancy Using Hyperpolarized Carbon-13 Technology
$400,000Terence P Gade · University Of Pennsylvania · DP5 · FY2015 · OD
SBIR PHASE I - TOPIC 405 - PROJECT TITLE: IN VIVO PHARMACOTYPING OF COMBINATION THERAPY IN PRIMARY BRAIN TUMORSFIRM FIXED PRICE - POP: 09/16/2020 - 0
$400,000Christian Knoopke · Lodestone Biomedical, Llc · N43 · FY2020 · CA
Molecular Mechanisms Regulating TLR Signaling and Macrophage Activation.
$400,000Shao-Cong Sun · University Of Tx Md Anderson Can Ctr · R01 · FY2017 · AI
Molecular Mechanisms Regulating TLR Signaling and Macrophage Activation.
$400,000Shao-Cong Sun · University Of Tx Md Anderson Can Ctr · R01 · FY2015 · AI
Developing a Novel Biologic Therapy to Eradicate Brain Cancer and Brain Metastasis
$400,000Donald Davidson · Creative Biotherapeutics, Llc · R43 · FY2024 · CA
Phase I/II Randomized Tiral of Adoptive Lymphocyte Transfer in Ovarian Cancer
$400,000George Coukos · University Of Pennsylvania · R01 · FY2014 · FD
Phase I/II Randomized Tiral of Adoptive Lymphocyte Transfer in Ovarian Cancer
$400,000George Coukos · University Of Pennsylvania · R01 · FY2008 · FD
(IND 102,133) Inhibition of Aurora Kinase A as Treatment For Melanoma
$400,000Jeffrey A Sosman · Vanderbilt University · R01 · FY2013 · FD
Regulation and function of nonlymphoid organ CD103 dendritic cells
$400,000Stephanie S Watowich · University Of Tx Md Anderson Can Ctr · R01 · FY2016 · AI
The immunosuppressive function of Checkpoint kinase 2 in gliomas
$400,000Crismita Clement Dmello · Northwestern University At Chicago · R01 · FY2024 · NS
Notch function in postnatal intestinal and mesenteric lymphatics
$400,000Carrie J. Shawber · Columbia University Health Sciences · R01 · FY2020 · DK
Image-Based Phenotyping of Hepatocellular Carcinoma Cell Survival Under Ischemic Stress: Toward Metabolic Imaging of Cancer Dormancy Using Hyperpolarized Carbon-13 Technology
$400,000Terence P Gade · University Of Pennsylvania · DP5 · FY2016 · OD
Cancer Biology Program (01)
$400,000Jonathan D. Chernoff · Research Inst Of Fox Chase Can Ctr · P30 · FY2021 · CA
Nanovectors for Characterization and Destruction of Breast Tumor Vasculature
$400,000Mauro Ferrari · University Of Texas Hlth Sci Ctr Houston · R01 · FY2007 · CA
Mechanism and therapeutic potential of microglia regulation in glioblastoma
$400,000Peiwen Chen · Northwestern University At Chicago · R01 · FY2022 · NS
First in Human Phase I/II clinical trial of ONC-392: Preserving CTLA-4 immune tolerance checkpoint for safer and more effective cancer immunotherapy
$400,000Pan Zheng · Oncoimmune, Inc. · R44 · FY2020 · CA
Activating TFEB to enhance the efficacy of immunotherapy for triple negative breast cancer
$400,000Daping Fan · Promilead, Llc · R41 · FY2025 · CA
Molecular Mechanisms Regulating TLR Signaling and Macrophage Activation.
$400,000Shao-Cong Sun · University Of Tx Md Anderson Can Ctr · R01 · FY2018 · AI
(IND 102,133) Inhibition of Aurora Kinase A as Treatment For Melanoma
$399,999Jeffrey A Sosman · Vanderbilt University · R01 · FY2010 · FD
Small Molecule CUL4 Inhibitors as Dual Precision Oncology and Immuno-Oncology Drugs
$399,999Scott D Eliasof · Culnexin Therapeutics, Inc. · R41 · FY2021 · CA
Chemosensitization of Glioblastoma by Propentofylline
$399,998Nhan L Tran · Oleolive, Inc. · R41 · FY2022 · CA
Modulation of cancer induced immune suppression via inhibition of SCD1
$399,986Karen E Hayes · Modulation Therapeutics, Inc. · R44 · FY2022 · CA